Patents by Inventor Joseph P. Vacca

Joseph P. Vacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRE1 small molecule inhibitors
    Patent number: 11945784
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: April 2, 2024
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Sarah Elizabeth Bettigole
  • Pyrazole pyrimidine derivative and uses thereof
    Patent number: 11925641
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: March 12, 2024
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventors: Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph P. Vacca, Dansu Li
  • DRUG CONJUGATES AND USES THEREOF
    Publication number: 20240066135
    Abstract: The invention generally relates to the design and production of drug conjugates, and specifically conjugates of antibiotic agents to cationic and non-cationic molecular transporters.
    Type: Application
    Filed: September 9, 2021
    Publication date: February 29, 2024
    Inventors: Jacob T. RENDELL, Lewis F. NEVILLE, Joseph P. VACCA
  • COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20230303489
    Abstract: Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
    Type: Application
    Filed: November 7, 2022
    Publication date: September 28, 2023
    Inventors: Duane A. Burnett, Joseph P. Vacca
  • IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20230271935
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: February 28, 2023
    Publication date: August 31, 2023
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE
    Publication number: 20230233562
    Abstract: Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).
    Type: Application
    Filed: January 25, 2023
    Publication date: July 27, 2023
    Inventors: Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah
  • IRE1 small molecule inhibitors
    Patent number: 11649224
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: May 16, 2023
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • IRE1 small molecule inhibitors
    Patent number: 11634403
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: April 25, 2023
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • Compounds, compositions and methods of use
    Patent number: 11542233
    Abstract: Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 3, 2023
    Assignee: Aquinnah Pharmaceuticals, Inc.
    Inventors: Duane A. Burnett, Joseph P. Vacca
  • IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20220356168
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: December 2, 2019
    Publication date: November 10, 2022
    Inventors: Joseph P. Vacca et al., Sarah Elizabeth Bettigol
  • COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20220265656
    Abstract: Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.
    Type: Application
    Filed: May 15, 2020
    Publication date: August 25, 2022
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20220251065
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: February 15, 2021
    Publication date: August 11, 2022
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20220227730
    Abstract: Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 21, 2022
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • BIFUNCTIONAL COMPOUNDS
    Publication number: 20220153751
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: BioTheryX, Inc.
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Frank Mercurio, Robert W. Sullivan, Joseph P. Vacca
  • Bifunctional compounds
    Patent number: 11236103
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca
  • IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20220024878
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Inventors: Joseph P. Vacca et al., Sarah Elizabeth Bettigole
  • PYRAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20220017493
    Abstract: The present invention provides pyrazole derivatives, e.g., a compound of Formula (I), and their uses in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Application
    Filed: July 26, 2021
    Publication date: January 20, 2022
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Dansu Li, Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah, Avanthika Venkatachalam
  • IRE1 SMALL MOLECULE INHIBITORS
    Publication number: 20210284628
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: May 6, 2021
    Publication date: September 16, 2021
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF
    Publication number: 20210251992
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Application
    Filed: March 29, 2021
    Publication date: August 19, 2021
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph P. Vacca, Dansu Li
  • SMALL MOLECULE IRE1-ALPHA INHIBITORS
    Publication number: 20210238167
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Application
    Filed: March 30, 2021
    Publication date: August 5, 2021
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos-Ruiz, Joseph P. Vacca